The use of aloe vera in cancer radiation: An updated comprehensive review.
CONCLUSIONS: There is contradictory evidence for the use of aloe vera in the setting of radiation in regards to its efficacy in the prevention and treatment of radiation-induced adverse effects. PMID: 31003648 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 22, 2019 Category: Cancer & Oncology Authors: Farrugia CE, Burke ES, Haley ME, Bedi KT, Gandhi MA Tags: Complement Ther Clin Pract Source Type: research

Use of complementary and alternative medicine among breast cancer patients in Hungary: A descriptive study.
This study aimed to explore the prevalence of the use of complementary and alternative medicine (CAM) before diagnosis and during oncology therapy, and reveal the disclosure of CAM use among Hungarian breast cancer patients. MATERIALS AND METHODS: In a cross-sectional survey a self-administered questionnaire was used covering patients' demographics, oncology-related variables and various aspects of CAM use. Data were collected from 135 patients. Data analysis included descriptive analysis and Chi-square tests. RESULTS: The prevalence of CAM use was 52.6% before diagnosis while it was 84.4% during therapy. The mos...
Source: Clinical Breast Cancer - April 22, 2019 Category: Cancer & Oncology Authors: Sárváry A, Sárváry A Tags: Complement Ther Clin Pract Source Type: research

Overexpression of ECT2 is a strong poor prognostic factor in ER(+) breast cancer.
Abstract Epithelial cell transforming sequence 2 (ECT2) is a guanine nucleotide exchange factor encoded by the ECT2 gene, which is located on the 3q26.31 chromosomal region and is directly associated with the occurrence of cancers. The aim of the present study was to examine the expression and prognostic importance of ECT2 in various breast cancer subtypes using the online tools, Gene Expression Profiling Interactive Analysis, Kaplan-Meier-plotter and bc-GenExMiner. ECT2 mRNA expression was significantly different in oestrogen receptor ER(+) breast cancer; overexpression of ECT2 was associated with poor prognosis ...
Source: Clinical Breast Cancer - April 12, 2019 Category: Cancer & Oncology Authors: Xiu Y, Liu W, Wang T, Liu Y, Ha M Tags: Mol Clin Oncol Source Type: research

The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis.
Conclusions: This meta-analysis shows that the addition of platinum to chemotherapy regimens in the neoadjuvant setting increases pCR rate in BRCA - mutated as compared to wild-type TNBC patients. However, this trend did not achieve statistical significance. Trial registration: CRD42018092341. PMID: 30962858 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 11, 2019 Category: Cancer & Oncology Authors: Caramelo O, Silva C, Caramelo F, Frutuoso C, Almeida-Santos T Tags: Hered Cancer Clin Pract Source Type: research

Increased breast cancer risk in women with neurofibromatosis type 1: a meta-analysis and systematic review of the literature.
Abstract Background: Neurofibromatosis type 1 (NF1) is a cancer predisposing syndrome. Studies suggest that women
Source: Clinical Breast Cancer - April 11, 2019 Category: Cancer & Oncology Authors: Suarez-Kelly LP, Yu L, Kline D, Schneider EB, Agnese DM, Carson WE Tags: Hered Cancer Clin Pract Source Type: research

Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.
CONCLUSION: Clinically-tested patients with breast and ovarian cancer in two large, diverse states had 8% to 15% prevalence of actionable pathogenic variants. Substantial testing gaps and disparities among patients with ovarian cancer are targets for improvement. PMID: 30964716 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 9, 2019 Category: Cancer & Oncology Authors: Kurian AW, Ward KC, Howlader N, Deapen D, Hamilton AS, Mariotto A, Miller D, Penberthy LS, Katz SJ Tags: J Clin Oncol Source Type: research

GTSE1 is involved in breast cancer progression in p53 mutation-dependent manner.
CONCLUSION: Our results reveal that GTSE1 played a key role in the progression of breast cancer, indicating that GTSE1 could serve as a novel biomarker to aid in the assessment of the prognosis of breast cancer. PMID: 30961661 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 8, 2019 Category: Cancer & Oncology Authors: Lin F, Xie YJ, Zhang XK, Huang TJ, Xu HF, Mei Y, Liang H, Hu H, Lin ST, Luo FF, Lang YH, Peng LX, Qian CN, Huang BJ Tags: J Exp Clin Cancer Res Source Type: research

Impact of the 2018 ASCO/CAP HER2 Guideline Focused Update.
CONCLUSIONS: The 2018 guidelines decrease the rate of HER2 equivocal and positive breast cancer and reduce repeat HER2 testing on excision specimens. Approximately 0.4% of patients will become newly ineligible for anti-HER2 therapy. PMID: 30958889 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 8, 2019 Category: Cancer & Oncology Authors: Gordian-Arroyo AM, Zynger DL, Tozbikian GH Tags: Am J Clin Pathol Source Type: research

Optimal timing for pegfilgrastim administration in Japanese breast cancer patients receiving intermediate-risk chemotherapies: response to study by Hayama et al.
PMID: 30953273 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 5, 2019 Category: Cancer & Oncology Authors: Henry DH, Weycker D, Bensink M, Gawade P, Belani R Tags: Int J Clin Pharm Source Type: research

A synonymous VHL variant in exon 2 confers susceptibility to familial pheochromocytoma and von Hippel-Lindau disease.
CONCLUSION: A recurrent synonymous VHL variant (c.414A>G, p.Pro138Pro) confers susceptibility to PHEO and VHL disease through splice disruption, leading to VHL dysfunction. This finding indicates that certain synonymous VHL variants may be clinically relevant and should be considered in genetic testing and surveillance settings. The observation that other coding VHL variants can exclude exon 2 suggests that dysregulated splicing may be an underappreciated mechanism in VHL-mediated tumorigenesis. PMID: 30946460 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 4, 2019 Category: Cancer & Oncology Authors: Flores SK, Cheng Z, Jasper AM, Natori K, Okamoto T, Tanabe A, Gotoh K, Shibata H, Sakurai A, Nakai T, Wang X, Zethoven M, Balachander S, Aita Y, Young W, Zheng S, Takekoshi K, Nakamura E, Tothill RW, Aguiar RCT, Dahia PLM Tags: J Clin Endocrinol Metab Source Type: research

Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Tools.
PMID: 30943126 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 3, 2019 Category: Cancer & Oncology Authors: Foldi J, O'Meara T, Marczyk M, Sanft T, Silber A, Pusztai L Tags: J Clin Oncol Source Type: research

Association of leukocyte DNA methylation changes with dietary folate and alcohol intake in the EPIC study.
CONCLUSIONS: Alcohol intake was associated with methylation levels at two CpG sites. Evidence from DMR and FL analyses indicated that dietary folate and alcohol intake may be associated with genomic regions with tumor suppressor activity such as the GSDMD and HOXA5 genes. These results were in line with the hypothesis that epigenetic mechanisms play a role in the association between folate and alcohol, although further studies are warranted to clarify the importance of these mechanisms in cancer. PMID: 30940212 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 2, 2019 Category: Cancer & Oncology Authors: Perrier F, Viallon V, Ambatipudi S, Ghantous A, Cuenin C, Hernandez-Vargas H, Chajès V, Baglietto L, Matejcic M, Moreno-Macias H, Kühn T, Boeing H, Karakatsani A, Kotanidou A, Trichopoulou A, Sieri S, Panico S, Fasanelli F, Dolle M, Onland-Moret C, Slui Tags: Clin Epigenetics Source Type: research

Effect of Radiotherapy After Breast-Conserving Surgery Depending on the Presence of Tumor-Infiltrating Lymphocytes: A Long-Term Follow-Up of the SweBCG91RT Randomized Trial.
Fernö M, Karlsson P Abstract PURPOSE: The effects of radiotherapy (RT) on the basis of the presence of stromal tumor infiltrating lymphocytes (TILs) have not been studied. The purpose of this study was to analyze the association of TILs with the effect of postoperative RT on ipsilateral breast tumor recurrence (IBTR) in a large randomized trial. METHODS: In the SweBCT91RT (Swedish Breast Cancer Group 91 Radiotherapy) trial, 1,178 patients with breast cancer stage I and II were randomly assigned to breast-conserving surgery plus postoperative RT or breast-conserving surgery only and followed for a median...
Source: Clinical Breast Cancer - April 2, 2019 Category: Cancer & Oncology Authors: Kovács A, Stenmark Tullberg A, Werner Rönnerman E, Holmberg E, Hartman L, Sjöström M, Lundstedt D, Malmström P, Fernö M, Karlsson P Tags: J Clin Oncol Source Type: research

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
CONCLUSION: With longer follow-up, adjuvant paclitaxel and trastuzumab is associated with excellent long-term outcomes. Distribution of PAM50 intrinsic subtypes in small HER2-positive tumors is similar to that previously reported for larger tumors. PMID: 30939096 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 2, 2019 Category: Cancer & Oncology Authors: Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay M, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer B, Partridge AH, Hudis CA, Krop IE, B Tags: J Clin Oncol Source Type: research

Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: A model-based characterization approach.
, Trocóniz IF, Santisteban M Abstract AIM: Immunotherapy is a rising alternative to traditional treatment in breast cancer (BC) patients in order to transform cold into hot immune enriched tumours and improve responses and outcome. A computational modelling approach was applied to quantify modulation effects of immunotherapy and chemotherapy response on tumour shrinkage and progression-free survival (PFS) in naïve BC patients. METHODS: Eighty-three Her2-negative BC patients were recruited for neoadjuvant chemotherapy with or without immunotherapy based on dendritic cell vaccination. Sequential tum...
Source: Clinical Breast Cancer - April 1, 2019 Category: Cancer & Oncology Authors: P Solans B, López-Díaz de Cerio A, Elizalde A, Pina LJ, Inogés S, Espinós J, Salgado E, Mejías LD, Trocóniz IF, Santisteban M Tags: Br J Clin Pharmacol Source Type: research

Vitamin D and breast cancer: A systematic review and meta-analysis of observational studies.
Abstract CONTEXT: Breast cancer (BC) is the most common malignancy among women in the US. Vitamin D status and intakes are thought to be inversely associated with BC occurrence. OBJECTIVES: In our systematic review and meta-analysis, we evaluated evidence linking serum 25(OH)D (both in serum and diet) with breast cancer (BC) occurrence. DATA SOURCES AND EXTRACTION: Only observational studies from databases such as PubMed and Cochrane (January 1st 2000 through March 15th, 2018) were included using PRISMA guidelines. Publication bias and consistency upon replication were assessed, while harmonizing risk ra...
Source: Clinical Breast Cancer - March 26, 2019 Category: Cancer & Oncology Authors: Hossain S, Beydoun MA, Beydoun HA, Chen X, Zonderman AB, Wood RJ Tags: Clin Nutr ESPEN Source Type: research

Influence of ABCB1 C3435T and C1236T gene polymorphisms on tumour response to docetaxel-based neo-adjuvant chemotherapy in locally advanced breast cancer patients of South India.
CONCLUSION: The tumour response to docetaxel was significantly influenced by the SNP C1236T of ABCB1 gene coding for the P-gp. However, when adjusted for other non-genetic factors, neither of the ABCB1 variants were found to be associated with tumour response to docetaxel-based NACT in LABC patients of South India. PMID: 30637776 [PubMed - indexed for MEDLINE] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 22, 2019 Category: Cancer & Oncology Authors: Priyadarshini R, Raj GM, Kayal S, Ramesh A, Shewade DG Tags: J Clin Pharm Ther Source Type: research

Minimally Invasive Management of Secondary Liver Cancer.
This article provides a comprehensive review of crucial concepts when managing secondary liver cancer minimally invasively, a summary of the up-to-date literature, and a discussion of the development of the application of this technique over time. PMID: 30851825 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 12, 2019 Category: Cancer & Oncology Authors: Yohanathan L, Cleary SP Tags: Surg Oncol Clin N Am Source Type: research

Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming.
CONCLUSION: A number of converging phenotypes outline a stress-responsive mechanism for SETDB1 and SETDB2 activation and subsequent increased survival, providing novel insights into epigenetic biology. A clearer understanding of how SETDB1/2-mediated transcriptional reprogramming can subvert treatment responses will be invaluable in improving length and efficacy of modern therapies. PMID: 30850015 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 8, 2019 Category: Cancer & Oncology Authors: Torrano J, Al Emran A, Hammerlindl H, Schaider H Tags: Clin Epigenetics Source Type: research

The association of five preoperative serum tumor markers and pathological features in patients with breast cancer.
CONCLUSION: Preoperative levels of CEA, CA153, and FER exhibit low diagnostic accuracy for breast cancer (stage I-III). CA153 correlates with tumor burden, suggesting its prognostic value. The five serum markers do not correlate with molecular subtypes. PMID: 30843272 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 6, 2019 Category: Cancer & Oncology Authors: Lian M, Zhang C, Zhang D, Chen P, Yang H, Yang Y, Chen S, Hong G Tags: J Clin Lab Anal Source Type: research

BRCA mutation testing for ovarian cancer in the context of available targeted therapy: Survey and consensus of Hong Kong specialists.
CONCLUSIONS: Accessibility of BRCAmut testing to all at-risk individuals will be achievable through improvements in testing affordability, as well as widened availability of accredited testing and genetic counseling facilities. PMID: 30838787 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 6, 2019 Category: Cancer & Oncology Authors: Kwong A, Cheng KD, Hsue CV, Hui SK, Leung CR, Leung KA, Ngan KR, Soong SI Tags: Asia Pac J Clin Oncol Source Type: research

Use of dietary supplements containing soy isoflavones and breast cancer risk among women aged > 50  y: a prospective study.
CONCLUSIONS: In this cohort of women aged>50 y, we report opposing associations of soy supplements with ER-positive and ER-negative breast cancer risk. Our results also caution against the use of these supplements in women with a family history of breast cancer. Whether the risk profile of soy supplements could be more favorable among premenopausal or recently postmenopausal women deserves further investigation. PMID: 30831601 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 4, 2019 Category: Cancer & Oncology Authors: Touillaud M, Gelot A, Mesrine S, Bennetau-Pelissero C, Clavel-Chapelon F, Arveux P, Bonnet F, Gunter M, Boutron-Ruault MC, Fournier A Tags: Am J Clin Nutr Source Type: research

68Ga-DOTATOC PET/CT Differentiates Meningioma From Dural Metastases.
Abstract A 77-year-old woman with history of breast cancer presented with 2 unclear dural contrast-enhancing lesions on MRI; differential diagnoses were breast cancer metastases and meningiomas. On Ga-DOTATOC PET/CT, the temporal lesion showed high uptake and was classified as meningioma, whereas the lesion at the falx showed barely any Ga-DOTATOC uptake uncharacteristic for meningioma and suggestive for a brain metastasis. After resection, histological specimens from the temporal lesion showed meningioma tissue with distinct SSTR2A expression, whereas the falx lesion revealed a breast cancer metastasis without si...
Source: Clinical Breast Cancer - March 1, 2019 Category: Cancer & Oncology Authors: Unterrainer M, Ruf V, Ilhan H, Vettermann FJ, Cyran CC, Niyazi M, Bartenstein P, Tonn JC, Albert NL Tags: Clin Nucl Med Source Type: research

68Ga-DOTANOC PET/CT in an Atypical Extraskeletal Paravertebral Hemangioma Mimicking as Neurogenic Tumor in a Known Case of Breast Cancer.
We present a case of extraskeletal paravertebral lesion detected in a known case of breast cancer with increased Ga-DOTANOC uptake later proved to be hemangioma. This is a novel finding and should be kept as a rare benign differential in evaluation of lesions with somatostatin receptor expression. PMID: 30829863 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 1, 2019 Category: Cancer & Oncology Authors: Vadi SK, Mittal BR, Parihar AS, Kumar R, Singh H, Singh G Tags: Clin Nucl Med Source Type: research

Recurrent MED12 exon 2 mutations in benign breast fibroepithelial lesions in adolescents and young adults.
CONCLUSIONS: As in adults, benign FELs in juvenile patients harbour recurrent MED12 exon 2 mutations. PMID: 30467240 [PubMed - indexed for MEDLINE] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 1, 2019 Category: Cancer & Oncology Authors: Pareja F, Da Cruz Paula A, Murray MP, Hoang T, Gularte-Mérida R, Brown D, da Silva EM, Sebastiao APM, Giri DD, Weigelt B, Reis-Filho JS, Brogi E Tags: J Clin Pathol Source Type: research

The New Possibility of Lymphoscintigraphy to Guide a Clinical Treatment for Lymphedema in Patient With Breast Cancer.
CONCLUSION: SGB was found to have a better therapeutic effect in the lymphedema patients with specific lymphoscintigraphic findings compared with CDT. Lymphoscintigraphy may be helpful in selecting the appropriate approach to lymphedema treatment. Further well-designed prospective studies are warranted to validate the findings of this study. PMID: 30672753 [PubMed - indexed for MEDLINE] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 1, 2019 Category: Cancer & Oncology Authors: Seo KS, Suh M, Hong S, Cheon GJ, Lee SU, Jung GP Tags: Clin Nucl Med Source Type: research

Androgen receptor: A promising therapeutic target in breast cancer.
Abstract Breast cancer (BCa) is the second most common cancer worldwide and the most prevalent cancer in women. The majority of BCa cases are positive (+) for the estrogen receptor (ER+, 80%) and progesterone receptor (PR+, 65%). Estrogen and progesterone hormones are known to be involved in cancer progression, and thus hormonal deprivation is used as an effective treatment for ER+PR+ BCa subtypes. However, some ER+PR+ BCa patients develop resistance to such therapies. Meanwhile, chemotherapy is the only available treatment for ER-PR- BCa tumors. Another hormone receptor known as the androgen receptor (AR) has als...
Source: Clinical Breast Cancer - March 1, 2019 Category: Cancer & Oncology Authors: Vasiliou SK, Diamandis EP Tags: Crit Rev Clin Lab Sci Source Type: research

Estrogen receptor- α-miR-1271-SNAI2 feedback loop regulates transforming growth factor-β-induced breast cancer progression.
CONCLUSIONS: Our data uncover the ERα-miR-1271-SNAI2 feedback loop and provide a mechanism to explain the TGF-β network in breast cancer progression. PMID: 30823890 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 1, 2019 Category: Cancer & Oncology Authors: Liu BW, Yu ZH, Chen AX, Chi JR, Ge J, Yu Y, Cao XC Tags: J Exp Clin Cancer Res Source Type: research

Prognostic role of glycolysis for cancer outcome: evidence from 86 studies.
The objective of this study was to investigate the prognostic significance of glycolysis-related proteins. MATERIALS AND METHODS: We searched MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, using Pubmed and Ovid as search engines and Google Scholar from inception to April 2017. Eighty-six studies with 12,002 patients were included in the study. RESULTS: Our pooled results identified that glycolysis-related proteins in cancers were associated with shorter overall survival of colorectal cancer (HR 2.33, 95% CI 1.38-3.93, P = 0.002), gastric can...
Source: Clinical Breast Cancer - March 1, 2019 Category: Cancer & Oncology Authors: Yu M, Chen S, Hong W, Gu Y, Huang B, Lin Y, Zhou Y, Jin H, Deng Y, Tu L, Hou B, Jian Z Tags: J Cancer Res Clin Oncol Source Type: research

Vessel co-option in cancer.
Abstract All solid tumours require a vascular supply in order to progress. Although the ability to induce angiogenesis (new blood vessel growth) has long been regarded as essential to this purpose, thus far, anti-angiogenic therapies have shown only modest efficacy in patients. Importantly, overshadowed by the literature on tumour angiogenesis is a long-standing, but continually emerging, body of research indicating that tumours can grow instead by hijacking pre-existing blood vessels of the surrounding nonmalignant tissue. This process, termed vessel co-option, is a frequently overlooked mechanism of tumour vascu...
Source: Clinical Breast Cancer - February 28, 2019 Category: Cancer & Oncology Authors: Kuczynski EA, Vermeulen PB, Pezzella F, Kerbel RS, Reynolds AR Tags: Nat Rev Clin Oncol Source Type: research

Trends in Opioid Use Among Older Survivors of Colorectal, Lung, and Breast Cancers.
CONCLUSION: Among three large populations of older cancer survivors, chronic opioid use varied by cancer. However, by 6 years after diagnosis, survivors were no longer more likely to be chronic users than controls. Strategies for appropriate pain management during and after cancer treatment should take into account the risks associated with chronic high-dose opioid use. PMID: 30817249 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 28, 2019 Category: Cancer & Oncology Authors: Salz T, Lavery JA, Lipitz-Snyderman AN, Boudreau DM, Moryl N, Gillespie EF, Korenstein D Tags: J Clin Oncol Source Type: research

The RNA binding protein RBMS3 inhibits the metastasis of breast cancer by regulating Twist1 expression.
CONCLUSIONS: In summary, our study revealed a novel mechanism of the RBMS3/Twsit1/MMP2 axis in the regulation of invasion and metastasis of breast cancer, which may become a potential molecular marker for breast cancer treatment. PMID: 30819235 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 28, 2019 Category: Cancer & Oncology Authors: Zhu L, Xi PW, Li XX, Sun X, Zhou WB, Xia TS, Shi L, Hu Y, Ding Q, Wei JF Tags: J Exp Clin Cancer Res Source Type: research

Insufficient radiofrequency ablation promotes the metastasis of residual hepatocellular carcinoma cells via upregulating flotillin proteins.
CONCLUSIONS: Our findings present new evidence that flotillins play a key role in the aggressive behaviors of residual cancer cells after insufficient RFA and provide new insights into the regulatory mechanism of Wnt/β-catenin signaling. PMID: 30820716 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 28, 2019 Category: Cancer & Oncology Authors: Zhang N, Li H, Qin C, Ma D, Zhao Y, Zhu W, Wang L Tags: J Cancer Res Clin Oncol Source Type: research

Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients.
CONCLUSION: Our study suggests that anthracyclines can be safely omitted in selected patients with HER2-positive breast cancer, who have cT1N0 or cT2N0 and achieved pathological complete response after receiving neoadjuvant chemotherapy. PMID: 30810890 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 27, 2019 Category: Cancer & Oncology Authors: Watanuki R, Hayashida T, Kawai Y, Kikuchi M, Nakashoji A, Yokoe T, Toyota T, Seki T, Takahashi M, Kitagawa Y Tags: Int J Clin Oncol Source Type: research

Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows.
PMID: 30811287 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 27, 2019 Category: Cancer & Oncology Authors: Regan MM, Fleming GF, Walley B, Francis PA, Pagani O Tags: J Clin Oncol Source Type: research

Preoperative Breast Magnetic Resonance Imaging in Women With Local Ductal Carcinoma in Situ to Optimize Surgical Outcomes: Results From the Randomized Phase III Trial IRCIS.
Rimareix F, Bonastre J, Garbay JR Abstract PURPOSE: We evaluated the addition of breast magnetic resonance imaging (MRI) to standard radiologic evaluation on the re-intervention rate in women with ductal carcinoma in situ (DCIS) undergoing breast-conserving surgery. PATIENTS AND METHODS: Women with biopsy-proven DCIS corresponding to a unifocal microcalcification cluster or a mass less than 30 mm were randomly assigned to undergo MRI or standard evaluation. The primary end point was the re-intervention rate for positive or close margins (
Source: Clinical Breast Cancer - February 27, 2019 Category: Cancer & Oncology Authors: Balleyguier C, Dunant A, Ceugnart L, Kandel M, Chauvet MP, Chérel P, Mazouni C, Henrot P, Rauch P, Chopier J, Zilberman S, Doutriaux-Dumoulin I, Jaffre I, Jalaguier A, Houvenaeghel G, Guérin N, Callonnec F, Chapellier C, Raoust I, Mathieu MC, Rimareix F Tags: J Clin Oncol Source Type: research

Implementing circulating tumor DNA analysis in a clinical laboratory: A user manual.
Abstract Liquid biopsy, the analysis of cell-free circulating tumor DNA (ctDNA), is becoming one of the most promising tools in oncology. It has already shown its usefulness in selecting and modulating therapy via remote analysis of the tumor genome and holds important promises in cancer therapy and management, such as assessing the success of key therapeutic steps, monitoring residual disease, early detection of relapses, and establishing prognosis. Yet, ctDNA analysis is technically challenging and its implementation in the laboratory raises multiple strategic and practical issues. As for oncology clinics, integ...
Source: Clinical Breast Cancer - February 26, 2019 Category: Cancer & Oncology Authors: Koessler T, Addeo A, Nouspikel T Tags: Adv Clin Chem Source Type: research

Patient preference study comparing hypofractionated versus conventionally fractionated whole-breast irradiation after breast-conserving surgery.
CONCLUSIONS: In this study, in which patients themselves selected the irradiation method, more patients tended to select CF-WBI. The frequency of G2 or higher dermatitis and breast pain was significantly lower in the HF-WBI group than in the CF-WBI group. Our results support the evidence for recommending HF-WBI after breast-conserving surgery while presenting aspects of patient preferences. PMID: 30796835 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 23, 2019 Category: Cancer & Oncology Authors: Kawaguchi H, Tsujino K, Miki M, Matsumoto Y, Ota Y, Hirokaga K, Takao S, Soejima T, Sasaki R Tags: Jpn J Clin Oncol Source Type: research

Smartphone problem-solving therapy to reduce fear of cancer recurrence among breast cancer survivors: an open single-arm pilot study.
CONCLUSIONS: Smartphone PST, a novel brief intervention to reduce FCR, was well accepted by breast cancer survivors and yielded a favorable effect on FCR. The efficacy of this newly developed smartphone PST needs to be confirmed in a future well-designed randomized controlled trial. PMID: 30793156 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 22, 2019 Category: Cancer & Oncology Authors: Imai F, Momino K, Katsuki F, Horikoshi M, Furukawa TA, Kondo N, Toyama T, Yamaguchi T, Akechi T Tags: Jpn J Clin Oncol Source Type: research

Biomarker discordance between primary breast cancer and bone or bone marrow metastases.
CONCLUSIONS: Biomarker discordance in bone or bone marrow lesions is common in patients with breast cancer. An accurate and thorough analysis of biomarkers and metastatic tumor properties is important for clinical decision-making. PMID: 30793198 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 22, 2019 Category: Cancer & Oncology Authors: Yuda S, Shimizu C, Yoshida M, Shiino S, Kinoshita T, Maeshima AM, Tamura K Tags: Jpn J Clin Oncol Source Type: research

Aberrant fatty acid profile and FFAR4 signaling confer endocrine resistance in breast cancer.
CONCLUSIONS: Our results establish a novel role of FFAR4 and its ligands in the complicated interactions between tissue lipid profile and cancer biology. FFAR4 signaling confers tamoxifen resistance in HRPBC cell line and FFAR4 expression can serve as a prognostic biomarker for tamoxifen-treated HRPBC patients. FFAR4 may serve as a potential target for anti-breast cancer therapies, especially in endocrine resistant cases. PMID: 30795784 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 22, 2019 Category: Cancer & Oncology Authors: Chu X, Zhou Q, Xu Y, Jiang J, Li Q, Zhou Q, Wu Q, Jin M, Wang H, Gu Y, Wang X, Wang B, He S, He X, Wu C, Zhang F, Zhang Y Tags: J Exp Clin Cancer Res Source Type: research

Long non-coding RNA LINC00968 attenuates drug resistance of breast cancer cells through inhibiting the Wnt2/ β-catenin signaling pathway by regulating WNT2.
CONCLUSION: Collectively, overexpressed LINC00968 contributes to reduced drug resistance in breast cancer cells by inhibiting the activation of the Wnt2/β-catenin signaling pathway through silencing WNT2. This study offers a new target for the development of breast cancer treatment. PMID: 30791958 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 21, 2019 Category: Cancer & Oncology Authors: Xiu DH, Liu GF, Yu SN, Li LY, Zhao GQ, Liu L, Li XF Tags: J Exp Clin Cancer Res Source Type: research

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients.
CONCLUSIONS: These results suggest that pCR in TNBC could be accurately predicted with an epigenetic signature of FERD3L and TRIP10 genes. Further prospective validation of these findings is warranted. PMID: 30786922 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 20, 2019 Category: Cancer & Oncology Authors: Pineda B, Diaz-Lagares A, Pérez-Fidalgo JA, Burgués O, González-Barrallo I, Crujeiras AB, Sandoval J, Esteller M, Lluch A, Eroles P Tags: Clin Epigenetics Source Type: research

Over-expression of both VEGF-C and Twist predicts poor prognosis in human breast cancer.
CONCLUSIONS: Our results suggested that co-expression of VEGF-C and Twist was associated with larger tumor size, higher numbers of lymph node involvement, D2-40-positive LVI, higher risk of distant metastasis, and worse DFS or OS in breast cancer patients. PMID: 30788837 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 20, 2019 Category: Cancer & Oncology Authors: Zhang YQ, Chen WL, Zhang F, Wei XL, Zeng D, Liang YK, Wu JD, Zhang LY, Guo CP, Zeng HC, Hao SS, Li RH, Huang WH, Zhang GJ Tags: Clin Transl Oncol Source Type: research

West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.
CONCLUSION: In the West German Study Group PlanB trial, 5-year outcomes for TC and EC-T were equally excellent. Six cycles of TC is an effective/safe option in human epidermal growth factor receptor 2-negative EBC with pN0 high genomic risk or pN1 EBC with genomically intermediate- to high-risk disease. PMID: 30785826 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 20, 2019 Category: Cancer & Oncology Authors: Nitz U, Gluz O, Clemens M, Malter W, Reimer T, Nuding B, Aktas B, Stefek A, Pollmanns A, Lorenz-Salehi F, Uleer C, Krabisch P, Kuemmel S, Liedtke C, Shak S, Wuerstlein R, Christgen M, Kates RE, Kreipe HH, Harbeck N, West German Study Group PlanB Investiga Tags: J Clin Oncol Source Type: research

Factors affecting tamoxifen metabolism in breast cancer patients; preliminary results of the French PHACS study (NCT01127295).
mas F Abstract In addition to the effect of CYP2D6 genetic polymorphisms, the metabolism of tamoxifen may be impacted by other factors with possible consequences on therapeutic outcome (efficacy, toxicity). This analysis focused on the pharmacokinetic-pharmacogenetic evaluation of tamoxifen in 730 adjuvant breast cancer patients included in a prospective multicenter study. Plasma concentrations of tamoxifen and six major metabolites, the genotype for 63 single nucleotide polymorphisms and co-medications were obtained 6 months after treatment initiation. Plasma concentrations of endoxifen were significantly associa...
Source: Clinical Breast Cancer - February 20, 2019 Category: Cancer & Oncology Authors: Puszkiel A, Arellano C, Vachoux C, Evrard A, Le Morvan V, Boyer JC, Robert J, Delmas C, Dalenc F, Debled M, Venat-Bouvet L, Jacot W, Suc E, Sillet Bach I, Filleron T, Roché H, Chatelut E, White-Koning M, Thomas F Tags: Clin Pharmacol Ther Source Type: research

Blockade of PDGFR β circumvents resistance to MEK-JAK inhibition via intratumoral CD8+ T-cells infiltration in triple-negative breast cancer.
CONCLUSION: These findings reveal a novel regulatory role of JAK2-mediated PDGFRβ proteolysis and provide an example of a PDGFRβ-mediated resistance mechanism upon specific target inhibition in TNBC. PMID: 30777101 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 18, 2019 Category: Cancer & Oncology Authors: Kalimutho M, Sinha D, Mittal D, Srihari S, Nanayakkara D, Shafique S, Raninga P, Nag P, Parsons K, Khanna KK Tags: J Exp Clin Cancer Res Source Type: research

Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer.
Abstract Trastuzumab is a milestone in the treatment of human epidermal growth factor receptor 2 positive (HER2+) breast cancer (BC), in both the early and metastatic settings. Over the last two decades, clinical trials have established the good safety profile of trastuzumab. Cardiotoxicity remains the most frequent adverse event, more commonly exemplified by an asymptomatic decline in the left ventricular ejection fraction rather than congestive heart failure. Results from several long-term (>5 years) safety analyses have been recently published, with the inherent evidence substantially confirming the findings...
Source: Clinical Breast Cancer - February 18, 2019 Category: Cancer & Oncology Authors: Mazzotta M, Krasniqi E, Barchiesi G, Pizzuti L, Tomao F, Barba M, Vici P Tags: J Clin Med Source Type: research

The Needs Self-Rating Questionnaire for Breast Cancer (NSQ-BC): Development of a tool for the needs assessment of women with breast cancer in mainland China.
This study developed a Needs Self-rating Questionnaire for Breast Cancer (NSQ-BC) based on Maslow's hierarchy of needs for mainland Chinese patients. METHODS: The Delphi technique and pilot cross-sectional surveys (two rounds) were performed for item selection. In the Delphi technique, items were selected according to the experts' perspective on the item's significance (ie, 1-5 Likert-scale ratings of importance; mean > 4.0 and coefficients of variation
Source: Clinical Breast Cancer - February 17, 2019 Category: Cancer & Oncology Authors: Zhou K, Huo L, He X, Li M, An J, Wang W, Li J, Li X Tags: J Eval Clin Pract Source Type: research

Relationship between tumor-associated immune infiltrate and p16 staining over clinicopathological features in acral lentiginous melanoma.
This study aims to evaluate the association between composition of tumor-infiltrating lymphocytes (TIL) and expression of p16 in acral lentiginous melanoma (ALM), and their impact on prognosis. MATERIALS AND METHODS: A cohort of 148 surgical pathology specimens of ALM was studied. TIL were evaluated by immunohistochemical detection of CD3 and CD8, along with CD20, CD4, CD68, and CD163 in a subset of 43 cases. p16 protein expression was also investigated in all the cases. RESULTS: The median age was 66 years, median Breslow thickness was 6.0 mm, grade III TIL was found in 28.4% and lymph nodes were invol...
Source: Clinical Breast Cancer - February 16, 2019 Category: Cancer & Oncology Authors: Castaneda CA, Castillo M, Torres-Cabala C, Bernabe LA, Casavilca S, Villegas V, Sanchez J, de la Cruz M, Dunstan J, Cotrina JM, Gomez HL, Chavez C, Landa-Baella MP, Tello K, Felix BF, Abugattas J Tags: Clin Transl Oncol Source Type: research